HRH3 and Alzheimer disease: While numerous preclinical studies have demonstrated the potential of various H3R antagonists and inverse agonists to enhance the cognitive abilities in rodents, clinical trials involving agents such as GSK239512 and ABT-288 have yielded limited efficacy in improving cognitive functions among patients with mild-to-moderate AD.